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ABSTRACT 
A multicentre study compared tianeptine (37.5 mg/day), an original psychotropic compound 
characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, 
mianserin (60 mg/day) and a reference anxiolytic, alprazolam (1.5 mg/day), in the treatment of 
152 patients fulfilling DSM-III-R criteria for adjustment disorder with mixed emotional features 
(anxiety and depression). The study used a double-blind parallel design over a 6-week period. 
Clinical assessments included the Clinical Global Impressions (CGI), the Montgomery and Asberg 
depression rating scale (MADRS), the Hamilton anxiety rating scale, a visual analogue scale, and 
the somatic scale of the system developed by the Association for the Methodology and 
Documentation in Psychiatry (AMDP). Results showed very similar improvement in the three 
treatment groups on all rating instruments. Moreover, the number of patients exhibiting adverse 
events did not differ among the three groups. Therefore, these results show similar 
antidepressant and anxiolytic activity for tianeptine, mianserin and alprazolam in patients 
suffering from adjustment disorder with mixed emotional features. These promising findings 
should however be confirmed in a placebo-controlled trial. 
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The essential feature of adjustment disorder is a maladaptive reaction to an identifiable 
psychosocial stressor, or stressors, that occurs within 3 months after onset of the stressor, and 
has persisted for no longer than 6 months (American Psychiatric Association, 1987). The 
maladaptive nature of the reaction is indicated either by impairment of occupational functioning 
or in usual social activities or relationships with others or by symptoms that are in excess of a 
normal and expectable reaction to the stressor (American Psychiatric Association, 1987). The 
disorder is apparently common. In a recent survey among psychiatric outpatients, 14.8 per cent 
exhibited adjustment disorder as main diagnosis (Samuelian et al., 1994). Among the nine 
subtypes of adjustment disorders defined in DSM-III-R, the most frequent ones appear to be with 
anxious mood, with depressed mood, with physical complaints, and with mixed emotional 
features (Samuelian et al., 1994). In the absence of adequate studies, the treatment of 
adjustment disorders is still an object of controversy. Psychotherapy is generally recommended; 
antidepressants as well as anxiolytics could be beneficial (Kaplan and Sadock, 1990). 
Tianeptine is a novel antidepressant agent which unlike other agents, stimulates the uptake of 
serotonin (Ansseau, 1993; Wilde and Benfield, 1995). In controlled trials, tianeptine exhibited 
both antidepressant and anxiolytic activity (Wilde and Benfield, 1995).  
In this context, the purpose of the present pilot study was to evaluate the efficacy of tianeptine in 
the treatment of adjustment disorders with mixed emotional features (anxiety and depression) 
in comparison to the antidepressant mianserin (Brogden et al., 1978) and to the anxiolytic 
benzodiazepine alprazolam (Jonas and Cohon, 1993). This preliminary study could shed some 
light on the usefulness of pharmacological agents in adjustment disorders. 
 
Table 1. Baseline characteristics of the sample 
 Tianeptine 
n = 49 
Mianserin 
n = 52 
Alprazolam 
n = 51 
P 
Age 43.6 ± 10.7 42.8 ± 12.6 44.2 ± 11.1 0.82 
Gender (F/M) 32/17 37/15 36/15 0.82 
Onset of present stress 
(days) 
95.9 ±118.2 86.9 ± 51.4 118.8 ± 252.3 0.59 
Duration of present episode 
(days) 
62.5 ±40.2 66.2 ± 45.1 60.7 ± 36.6 0.78 
MADRS 27.0 ± 7.3 28.4 ± 6.7 27.5 ± 5.5 0.54 
HARS 27.0 ± 5.7 27.7 ± 5.8 28.1 ± 5.9 0.64 
CGI 1 (severity of illness) 4.1 ± 0.7 4.2 ± 0.7 4.2 ± 0.6 0.62 
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DESIGN OF THE STUDY 
The study was performed between September 1992 and March 1994 in seven Belgian, three 
Swiss, and one French centres used to collaborating and exhibiting good reliability in clinical 
rating (see affiliations). The trial used a double-blind design with three parallel groups of 
patients randomly assigned to tianeptine (37.5 mg/day), mianserin (60 mg/day), or alprazolam 
(1.5 mg/day). After an optional run-in period of 7 days on placebo (3/day), the patients received 
ascending doses of active compounds during the first 3 days (tianeptine 12.5, 25, and 37.5 mg; 
mianserin 20, 40, and 60 mg; and alprazolam 0.5, 1, and 1.5 mg). All active compounds were 
then administered in three daily intakes. The duration of the study was 6 weeks. The daily dose 
was kept stable during the initial 2-week treatment period and could then be adapted according 
to efficacy and tolerability between 25 and 50 mg/day for tianeptine, between 40 and 80 
mg/day for mianserin, and between 1 and 2 mg/day for alprazolam. No other psychotropic 
drugs were permitted throughout the study period. The trial was monitored according to all 
principles of European and US ‘Good clinical practice’ (CPMP Working Party on Efficacy of 
Medicinal Products, 1990; Mathieu, 1990). 
SUBJECTS 
A total of 152 outpatients were included in the study: 49 in the tianeptine group, 52 in the 
mianserin group, and 51 in the alprazolam group. Patients were 47 males and 105 females, aged 
19-73 years, with a mean age (SD) of 43.5 (11.5) years. All subjects fulfilled DSM-III-R diagnostic 
criteria for adjustment disorder with mixed emotional feature (anxiety and depression) (DSM-
III-R 309.28, American Psychiatric Association, 1987). In addition, the patients had total scores 
on Raskin depression and Covi anxiety scales of at least 7 with differences between the two 
scores less than 4 (Raskin et al., 1967; Covi et al., 1979). Patients presenting serious or 
uncontrolled medical illness were excluded from the study. The demographic and clinical 
characteristics of the patients are presented in Table 1. No statistically significant differences 
existed among the treatment groups.  
Finally, the protocol obtained approvals from the ethical committees of the various centres and 
all patients were fully informed of the purpose of the study and gave their consent. 
ASSESSMENTS 
Assessments were performed at baseline and after 1, 2, 4, and 6 weeks and included clinical 
global impressions (CGI) (Guy, 1976), the Montgomery and Asberg depression rating scale 
(MAPRS) (Montgomery and Asberg, 1979), the Hamilton anxiety rating scale (Hamilton, 1959), 
a global self-rated visual analogue scale, and the somatic scale of the systems developed by the 
Association for Methodology and Documentation in Psychiatry (Bobon et al., 1983). Physical 
examinations, including blood pressure, heart rate, and weight were performed at baseline as 
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well as after 2, 4, and 6 weeks; EKG’s and laboratory parameters were controlled at baseline and 
6 weeks later. 
DATA ANALYSIS 
Initially, the homogeneity of the three treatment groups was controlled, using one-way analysis 
of variance or Fisher’s exact test. All changes over time in ratings were completed by two-way 
analyses of variance (ANOVAs) with repeated measures and final scores were compared using 
one-way ANOVAs. All analyses used intent-to-treat samples with last observation carried 
forward as well as complete samples, but since the conclusions of this second analysis were 
similar, they will not be reported in this article. The number of treatment responders, defined by 
a decrease of initial scores of at least 50 per cent was compared using Fisher’s exact test. Results 
are presented as means and standard deviations. 
 
Figure 1. Changes over time in mean scores (± SD) on the MADRS among patients treated by tianeptine, mianserin, or 
alprazolam 
 
Figure 2. Changes over time in mean scores (± SD) on the Hamilton anxiety rating scale among patients treated by 
tianeptine, mianserin, or alprazolam 
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A total of 33 patients (21.7 per cent) did not complete the study. Their distribution and main 
reasons are presented in Table 2. 
Table 2. Distribution of reasons for premature withdrawal 
 Tianeptine Mianserin Alprazolam P 
Adverse event (n = 12) 1 8 3  
Major protocol violation 
(n = 2) 
1 1 0  
Lack of efficacy  
(n = 12) 
4 3 5  
Known cause unrelated 
to treatment 
(n = 3) 
1 0 2 0.08 
Lost to follow-up 
(n = 2) 
1 0 1  
Recovery (n = 2) 2 0 0  
Total 10 12 11  
 
EFFICACY 
MADRS. MADRS total scores did not exhibit any significant differences among the three groups 
in their changes over time (p = 0.92) (Figure 1) as well as in their final scores: 15.2 ± 9-3 with 
tianeptine, 14.9 ± 10.3 with mianserin, and 14.8 ± 10.3 with alprazolam (p = 0.98). In addition, 
the analysis of individual items of the MADRS did not reveal any significant difference among the 
treatment groups. 
The number of treatment responders did not differ among the three groups: 464 per cent with 
tianeptine, 50.0 per cent with mianserin, and 51.0 per cent with alprazolam (n.s.).  
Hamilton anxiety rating scale. Hamilton total scores did not exhibit any significant differences 
among the three groups in their changes over time (p = 0.80) (Figure 2) as well as in their final 
scores: 14.3 ± 9.3 with tianeptine, 14.2 ± 10.5 with mianserin, and 13.8 ± 11.1 with alprazolam 
(p = 0.97. In addition, the analysis of psychic and somatic anxiety subscores as well as individual 
items of the Hamilton anxiety rating scale did not reveal any significant difference among the 
treatment groups. 
CGI. Final CGI scores did not differ among the three treatment groups: for CGI-1 (severity of 
illness), 2.4 ± 1.4 for tianeptine, 2.5 ± 1.5 for mianserin, and 2.2 ± 1.6 for alprazolam (p = 0.68); 
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for CGI-2 (global improvement), respectively 1.5 ± 1.2, 1.6 ± 1.3, and 1.4 ± 1.3 (p = 0.57); and 
for CGI-3 (efficacy index), respectively 2.5 ± 1.1, 2.2 ± 1.3, and 2.4 ± 1.3 (p = 0.3 1). 
Visual analogue scale. Self-rated visual analogue scales did not exhibit any significant difference 
among the three groups in their changes over time (p = 0.82) as well as in their final scores: 5.8 
± 2.8 with tianeptine, 5.5 ± 2.9 with mianserin, and 5.9 ± 3.1 with alprazolam (p = 0.83). 
SAFETY 
The number of patients exhibiting adverse events during the study period did not differ 
significantly among the three groups: 14 patients with tianeptine, 23 with mianserin, and 20 
with alprazolam (p = 0.25). The distribution of individual adverse events is presented in Table 
3.  
Vital signs and laboratory parameters did not exhibit any significant modifications. 
 
Table 3. Comparison of adverse events 
 Tianeptine (n = 49) Mianserin (n = 52) Alprazolam (n =51) P 
 N % N % N %  
Dizziness 1 2.0 3 5.8 1 2. 0.62 
Headache 3 6.1 3 5.8 3 5.9 1.00 
Appetite increase 0 0 4 7.7 1 2.0 0.13 
Somnolence 4 8.2 4 7.7 4 7.8 1.00 
Constipation 0 0 4 7.7 1 2.0 0.13 
Nausea 4 8.2 3 5.8 2 3.9 0.64 
Fatigue 1 2.0 4 7.7 5 9.8 0.32 
 
Discussion 
The results of the present study support similar efficacy and tolerability for tianeptine, 
mianserin, and alprazolam in patients suffering from adjustment disorder with mixed emotional 
features. The lack of significant differences between the treatments appears both for the 
depressive symptomatology, as measured by the MADRS, and the anxious symptomatology, as 
measured by the Hamilton anxiety rating scale. Moreover, the global assessments completed by 
the clinician (CGI) as well as by the patient him/herself (visual analogue scale) support the 
equivalence in efficacy among the three drugs.  
Regarding safety, the number and the severity of side-effects did not significantly differ between 
tianeptine, mianserin and alprazolam.  
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It is interesting to note that in this particular indication, antidepressants such as tianeptine and 
mianserin exhibit similar efficacy compared to a benzodiazepine anxiolytic, such as alprazolam. 
Tianeptine presents a particular profile which could theoretically make it a drug of choice in 
adjustment disorders with both depression and anxiety. First, animal models have shown that 
tianeptine reduces the hypothalamic-pituitary-adrenal (HPA) response to stress, antagonizes 
stress-induced behavioural deficits and prevents stress-induced dentritic atrophy (Delbende et 
al., 1991; Broqua et al., 1992; Fontanges et al., 1993; McEwan et al., 1993). Adjustment disorder 
can be interpreted as a pathological response to stress (American Psychiatric Association, 
1987). Second, tianeptine has demonstrated a particular efficacy in anxious depression (Guelfi et 
al., 1989).  
The coexistence of anxiety and depression is common and frequently poses treatment challenges 
in the clinical setting. Mixed anxiety-depressive disorder has been added in ICD-10 (World 
Health Organization, 1992) and as an appendix in DSM-IV (American Psychiatric Association, 
1994). Mixed anxiety-depressive disorder is suggested to have a prevalence of between 1 per 
cent and 10 per cent (Wittchen and Essau, 1993) and seems to be most highly represented in the 
primary care patient population. A recent study in a primary-care clinic found that 19-2 per cent 
of patients had a comorbid anxiety and depressive disorder and 12-8 per cent a mixed 
anxietydepressive disorder (Stein et al., 1995). The optimal treatment for this mixed disorder is 
still to be defined (Zajecka and Ross, 1995) and due to its particular profile, tianeptine could 
represent a drug of choice. 
The results of the present study should however be considered as preliminary due to the lack of 
a placebo group. Indeed, little is known about the natural evolution of adjustment disorder and 
the improvement noted in our trial could simply correspond to a spontaneous evolution. 
Therefore, a placebo-controlled trial is clearly needed in order to place tianeptine more precisely 
in the treatment of adjustment disorder with mixed emotional features. 
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